SABSW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SA

Volume

1.00K

Loading chart

SA

SABSWSAB Biotherapeutics, Inc. Warrant

SABSW

Pay with—

Available Balance0.00

SA

Mkt Cap

N/A

Volume

1.00K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsSAB Biotherapeutics announced the pricing of an $85 million public offering consisting of 19.3 million shares at $3.85 per share and pre-funded warrants. The company plans to use proceeds to fund development of SAB-142, its clinical-stage candidate for type 1 diabetes, through ongoing Phase 2b trials and related activities. The offering is expected to close on March 19, 2026.Benzinga · Mar 18, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsSAB Biotherapeutics (Nasdaq: SABS) announced a public offering of 19.3 million shares at $3.85 per share and 2.75 million pre-funded warrants, expected to raise approximately $85 million in gross proceeds. The company plans to use the funds to advance development of SAB-142, its lead candidate for type 1 diabetes, through ongoing clinical trials and related activities.GlobeNewswire Inc. · Mar 18, 2026

SAB BIO to Participate in Upcoming Investor ConferencesSAB Biotherapeutics announced that its management team will participate in two investor conferences in February 2026: the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company is developing SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes treatment.GlobeNewswire Inc. · Feb 4, 2026

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New DirectorSAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two decades of experience in biopharmaceutical development and clinical strategy. Both appointments are intended to support the company's advancement of SAB-142, its lead candidate for Type 1 Diabetes treatment, through clinical development and potential commercialization.GlobeNewswire Inc. · Jan 7, 2026

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1DSAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.GlobeNewswire Inc. · Dec 17, 2025

SILQFi Launches Omni Following Acquisition of OXOSILQFi has launched Omni, a new financial platform for small businesses, after acquiring OXO. The platform integrates point-of-sale, procurement, payments, and credit access to streamline merchant workflows and improve capital access in Saudi Arabia.Benzinga · Sep 16, 2025

SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesSAB BIO, a clinical-stage biopharmaceutical company, reported financial results for Q1 2025. The company made progress on its type 1 diabetes program, including positive Phase 1 data for its lead candidate SAB-142. SAB BIO also achieved manufacturing milestones and saw a decrease in R&D and G&A expenses.GlobeNewswire Inc. · May 9, 2025

SAB BIO to Participate in Upcoming Investor ConferencesSAB BIO, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences to discuss its lead asset, SAB-142, which targets type 1 diabetes with a disease-modifying approach.GlobeNewswire Inc. · Jan 31, 2025

SAb Biotherapeutics Rebrands as SAB BIONew name, logo and website updates, stock symbol will remain SABSGlobeNewswire Inc. · Jun 20, 2024

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsMIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst, Ph.D, and published online in the journal Diabetes®.GlobeNewswire Inc. · Jun 18, 2024

to start trading

SA

SABSWSAB Biotherapeutics, Inc. Warrant

SABSW

Pay with—

Available Balance0.00

Your PositionYou don't own any SABSW yet.

Related Tickers

Earnings